Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger

by Zacks Equity Research Published on December 06,2018

Shire's (SHPG) pending acquisition by Takeda Pharmaceuticals for $62 billion gets approval from shareholders of both the companies.

• AGN Quick QuoteAGNPositive Net Change
• INCY Quick QuoteINCYPositive Net Change
• BMRN Quick QuoteBMRNNegative Net Change
• SHPG Quick QuoteSHPGNo Net Change

• pharmaceuticals

Is the Options Market Predicting a Spike in Shire (SHPG) Stock?

by Zacks Equity Research Published on December 05,2018

Investors need to pay close attention to Shire (SHPG) stock based on the movements in the options market lately.

• SHPG Quick QuoteSHPGNo Net Change

• medical

Shire's Takhzyro Gets European Nod for Hereditary Angioedema

by Zacks Equity Research Published on December 03,2018

Shire's (SHPG) gets European approval for Takhzyro subcutaneous injection, for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.

• MRK Quick QuoteMRKPositive Net Change
• BMY Quick QuoteBMYNegative Net Change
• GILD Quick QuoteGILDPositive Net Change
• SHPG Quick QuoteSHPGNo Net Change

• pharmaceuticals

Shire-Takeda Deal Gets Phase I Conditional European Approval

by Zacks Equity Research Published on November 21,2018

Takeda's bid to acquire Shire (SHPG) receives conditional approval from the European Commission.

• JNJ Quick QuoteJNJNegative Net Change
• BMY Quick QuoteBMYNegative Net Change
• MRK Quick QuoteMRKPositive Net Change
• SHPG Quick QuoteSHPGNo Net Change

• pharmaceuticals

Shire's Filing Accepted by FDA for Gattex's Label Expansion

by Zacks Equity Research Published on November 14,2018

The FDA accepts Shire's (SHPG) sNDA and is expected to take action in March 2019.

• LLY Quick QuoteLLYPositive Net Change
• PFE Quick QuotePFEPositive Net Change
• BMY Quick QuoteBMYNegative Net Change
• SHPG Quick QuoteSHPGNo Net Change

• pharmaceuticals

Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3

by Zacks Equity Research Published on November 09,2018

Merrimack (MACK) discourages with Q3 loss, falling shy of estimates as well as deteriorates from the year-ago quarter's figure. Also, the company fails to reap any revenues in the period.

• SNY Quick QuoteSNYNegative Net Change
• AZN Quick QuoteAZNNegative Net Change
• MACK Quick QuoteMACKPositive Net Change
• SHPG Quick QuoteSHPGNo Net Change

• biotechs

Shire's (SHPG) Earnings, Revenues Miss Estimates in Q3

by Zacks Equity Research Published on November 02,2018

Shire (SHPG) misses earnings and revenue estimates in the third quarter of 2018. The company completes the sale of its Oncology franchise in the quarter.

• MRK Quick QuoteMRKPositive Net Change
• BMY Quick QuoteBMYNegative Net Change
• LLY Quick QuoteLLYPositive Net Change
• SHPG Quick QuoteSHPGNo Net Change

• pharmaceuticals

J&J's Stelara Succeeds in Phase III Ulcerative Colitis Study

by Zacks Equity Research Published on October 10,2018

J&J's (JNJ) Stelara induces clinical remission and response in ulcerative colitis patients who had failed prior therapy, per data from a phase III study.

• ABBV Quick QuoteABBVNegative Net Change
• PFE Quick QuotePFEPositive Net Change
• JNJ Quick QuoteJNJNegative Net Change
• SHPG Quick QuoteSHPGNo Net Change

• pharmaceuticals

Aldeyra Surges on Positive Dry Eye Study Data on Reproxalap

by Zacks Equity Research Published on September 27,2018

Aldeyra Therapeutics' (ALDX) dry eye candidate, reproxalap, achieves early onset of improvement in patients and a broad range of activity.

• AGN Quick QuoteAGNPositive Net Change
• BSTC Quick QuoteBSTCPositive Net Change
• ALDX Quick QuoteALDXPositive Net Change
• SHPG Quick QuoteSHPGNo Net Change

Is Shire (SHPG) a Suitable Stock for Value Investors Now?

by Zacks Equity Research Published on September 21,2018

Let's see if Shire plc (SHPG) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

• SHPG Quick QuoteSHPGNo Net Change

Company News For Sep 17, 2018

by Zacks Equity Research Published on September 17,2018

Companies In The News are: ADBE,LB,NI,SHPG

• NI Quick QuoteNINegative Net Change
• ADBE Quick QuoteADBEPositive Net Change
• SHPG Quick QuoteSHPGNo Net Change
• LB Quick QuoteLBPositive Net Change

Shire's ADHD Portfolio Remains Strong Amid Competition

by Zacks Equity Research Published on September 10,2018

Shire (SHPG) has a strong hold in the attention deficit hyperactivity disorder (ADHD) market despite facing competition.

• NVS Quick QuoteNVSNegative Net Change
• JNJ Quick QuoteJNJNegative Net Change
• GILD Quick QuoteGILDPositive Net Change
• SHPG Quick QuoteSHPGNo Net Change

Shire's Takhzyro Gets FDA Nod for Hereditary Angioedema

by Zacks Equity Research Published on August 24,2018

Shire???s (SHPG) Takhzyro gets approval from the FDA for the treatment of hereditary angioedema in patients 12 years of age and older. It is the first-of-its-kind mAb preventive treatment for the same.

• LGND Quick QuoteLGNDNegative Net Change
• CELG Quick QuoteCELGPositive Net Change
• GILD Quick QuoteGILDPositive Net Change
• SHPG Quick QuoteSHPGNo Net Change

Shire, Shionogi File NDA for Intuniv for Adults in Japan

by Zacks Equity Research Published on August 13,2018

Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.

• PFE Quick QuotePFEPositive Net Change
• JNJ Quick QuoteJNJNegative Net Change
• GILD Quick QuoteGILDPositive Net Change
• SHPG Quick QuoteSHPGNo Net Change

Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold

by Zacks Equity Research Published on August 13,2018

Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.

• SNY Quick QuoteSNYNegative Net Change
• GILD Quick QuoteGILDPositive Net Change
• FOLD Quick QuoteFOLDPositive Net Change
• SHPG Quick QuoteSHPGNo Net Change

Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q2

by Zacks Equity Research Published on August 08,2018

Merrimack's (MACK) loss is wider than expected in Q2 but narrower than the year-ago quarter's deficit. Meanwhile, the company did not generate any revenues in the reported quarter.

• ILMN Quick QuoteILMNPositive Net Change
• GILD Quick QuoteGILDPositive Net Change
• MACK Quick QuoteMACKPositive Net Change
• SHPG Quick QuoteSHPGNo Net Change

Shire's (SHPG) Earnings and Revenues Beat Estimates in Q2

by Zacks Equity Research Published on August 01,2018

During the second quarter of 2018, the boards of Takeda and Shire (SHPG) reached an agreement pursuant to which the former will acquire the entire issued and to-be-issued ordinary share capital of the latter.

• GILD Quick QuoteGILDPositive Net Change
• VNDA Quick QuoteVNDAPositive Net Change
• RARE Quick QuoteRARENegative Net Change
• SHPG Quick QuoteSHPGNo Net Change

Company News For Jul 11, 2018

by Zacks Equity Research Published on July 11,2018

Companies In The News are: SHPG,SJM,XRX,PCAR

• PCAR Quick QuotePCARPositive Net Change
• SJM Quick QuoteSJMPositive Net Change
• SHPG Quick QuoteSHPGNo Net Change
• XRX Quick QuoteXRXPositive Net Change

Is Shire (SHPG) a Great Stock for Value Investors?

by Zacks Equity Research Published on July 05,2018

Let's put Shire (SHPG) stock into this equation and find out if it is a good choice for value-oriented investors right now.

• SHPG Quick QuoteSHPGNo Net Change

Shire (SHPG) HAE Drug Gets FDA Nod for Pediatric Population

by Zacks Equity Research Published on June 22,2018

Shire (SHPG) gains FDA approval for expanding the label of its hereditary angioedema (HAE) drug, Cinryze, to include its usage among pediatric patients aged six years and older.

• BLRX Quick QuoteBLRXPositive Net Change
• SHPG Quick QuoteSHPGNo Net Change
• ACRX Quick QuoteACRXPositive Net Change
• CTLT Quick QuoteCTLTPositive Net Change

Allergan Requests Shareholders to Veto Management Change

by Zacks Equity Research Published on June 06,2018

Allergan (AGN) responds to shareholders stating that it is open to the latter's opinions. However, the company has requested them to vote against appointment of independent chairman.

• AGN Quick QuoteAGNPositive Net Change
• SHPG Quick QuoteSHPGNo Net Change
• SGYP Quick QuoteSGYPNo Net Change

Pfizer's Arthritis Drug Gets FDA Nod for Ulcerative Colitis

by Zacks Equity Research Published on May 31,2018

The FDA approves Pfizer's (PFE) sNDA seeking label expansion in third indication for Xeljanz to include moderately to severely active ulcerative colitis.

• PFE Quick QuotePFEPositive Net Change
• JNJ Quick QuoteJNJNegative Net Change
• ABBV Quick QuoteABBVNegative Net Change
• SHPG Quick QuoteSHPGNo Net Change

Should First Trust NASDAQ-100 Equal Weighted Index Fund (QQEW) Be on Your Investing Radar?

by Sweta Killa Published on May 18,2018

Style Box ETF report for QQEW

• QQQ Quick QuoteQQQPositive Net Change
• IWF Quick QuoteIWFPositive Net Change
• QQEW Quick QuoteQQEWPositive Net Change
• SHPG Quick QuoteSHPGNo Net Change

Nektar (NKTR) Q1 Loss Wider Than Expected, Sales Soar Y/Y

by Zacks Equity Research Published on May 14,2018

Nektar (NKTR) reports wider-than-expected loss in Q1 while revenues rise substantially year over year. It collaborates with Bristol-Myers for advancing immuno-oncology and immunology pipeline.

• BMY Quick QuoteBMYNegative Net Change
• LLY Quick QuoteLLYPositive Net Change
• SHPG Quick QuoteSHPGNo Net Change
• NKTR Quick QuoteNKTRNegative Net Change

Is First Trust NASDAQ-100 Equal Weighted Index Fund (QQEW) a Hot ETF Right Now?

by Sweta Killa Published on May 14,2018

Smart Beta ETF report for QQEW

• QQQ Quick QuoteQQQPositive Net Change
• IWF Quick QuoteIWFPositive Net Change
• QQEW Quick QuoteQQEWPositive Net Change
• SHPG Quick QuoteSHPGNo Net Change